{
    "doi": "https://doi.org/10.1182/blood.V114.22.2375.2375",
    "start_url": "https://ashpublications.org/blood/search-results?sort=Date+-+Oldest+First&f_ArticleTypeDisplayName=Meeting+Report&fl_SiteID=1000001&page=1365",
    "start_url_page_num": 1365,
    "is_scraped": "1",
    "article_title": "External Validation On Biological Basis of New Prognostic Index in Early Asymptomatic Chronic Lymphocytic Leukemia (CLL) Patients: The Gruppo Italiano Studio Linfomi (GISL) Experience. ",
    "article_date": "November 20, 2009",
    "session_type": "CLL - THERAPY, EXCLUDING TRANSPLANTATION POSTER I",
    "topics": [
        "chronic b-cell leukemias",
        "chronic lymphocytic leukemia",
        "zap-70 kinase",
        "alemtuzumab",
        "chromosome abnormality",
        "chromosome 13q deletion",
        "chromosome 17p deletion",
        "trisomy 12",
        "treatment outcome",
        "correlation studies"
    ],
    "author_names": [
        "Stefano Molica, MD",
        "Sonia Fabris, PhD",
        "Giovanna Cutrona, PhD",
        "Massimo Gentile, MD",
        "Emanuela Anna Pesce, PhD",
        "Francesco Di Raimondo, MD",
        "Caterina Musolino, MD",
        "Marco Gobbi, MD",
        "Nicola Di Renzo, MD",
        "Francesca Mauro, MD",
        "Renato Cantaffa, MD",
        "Maura Brugiatelli, MD",
        "Francesco Merli, MD",
        "Simonetta Zupo, PhD",
        "Caterina Mammi, PhD",
        "Luca Baldini, MD",
        "Francesco Angrilli, MD",
        "Gianni Quintana, MD",
        "Ugo Consoli, MD",
        "Giovanni Bertoldero, MD",
        "Emilio Iannitto, MD",
        "Paolo Di Tonno, MD",
        "Antonio Fragasso, MD",
        "Pellegrino Musto, MD",
        "Maria Cristina Cox, MD",
        "Gianluca Festini, PhD",
        "Vincenzo Callea, MD",
        "Stefano Sacchi, MD",
        "Agostino Cortelezzi, MD",
        "Giorgio Lambertenghi, MD",
        "Robert Foa\u0300, MD",
        "Antonino Neri, MD",
        "Massimo Federico, MD",
        "Manlio Ferrarini, MD",
        "Fortunato Morabito, MD"
    ],
    "author_affiliations": [
        [
            "Dip di Oncologia ed Ematologia, Azienda Ospedaliera Pugliese-Ciaccio, Catanzaro, Italy, Catanzaro, Italy, "
        ],
        [
            "Dipartimento Scienze Mediche - Ematologia 1 CTMO, Universita\u0300 di Milano -Fondazione IRCCS Policlinico, Milano, Italy, "
        ],
        [
            "Divisione di Oncologia Medica C, Istituto Nazionale per la Ricerca sul Cancro, IST, Genova, Italy, Genova, Italy, "
        ],
        [
            "Unita\u0300 Operativa di Ematologia, Azienda Ospedaliera dell'Annunziata, Cosenza, Cosenza, Italy, "
        ],
        [
            "GISL Trial Office, Modena, Modena, Italy, "
        ],
        [
            "Dipartimento di Scienze Biomediche, Divisione di Ematologia, Universita\u0300 di Catania & Ospedale Ferrarotto, Catania, Italy, Catania, Italy, "
        ],
        [
            "Divisione di Ematologia, Universita\u0300 di Messina, Messina, Italy, Messina, "
        ],
        [
            "Dipartimento di Ematologia e Oncologia, Universita\u0300 di Genova, Italy, Genova, Italy, "
        ],
        [
            "Unita\u0300 di Ematologia, Ospedale Vito Fazzi, Lecce, Italy, Lecce, Italy, "
        ],
        [
            "Divisione di Ematologia, Universita\u0300 La Sapienza, Roma, Italy, Roma, Italy, "
        ],
        [
            "Ematologia, Azienda Ospedaliera catanzaro, Catanzaro, Italy, "
        ],
        [
            "Divisione di Ematologia, Azienda Ospedaliera Papardo, Messina, Italy, Messina, Italy, "
        ],
        [
            "Unita\u0300 Operativa di Ematologia,, A.O. S. Maria Nuova, Reggio Emilia, Italy, Reggio Emilia, Italy, "
        ],
        [
            "SS Malattie Linfoproliferative, Istituto Nazionale per la Ricerca sul Cancro, IST, Genova, Italy, Genova, Italy, "
        ],
        [
            "Dipartimento di Oncologia ed Ematologia, Universita' di Modena e Reggio Emilia, Modena, Italy, "
        ],
        [
            "Division of Hematology, Fondazione IRCCS Ospedale Maggiore Policlinico, University of Milano, Torino, Italy, "
        ],
        [
            "Dipartimento di Ematologia, Ospedale Santo Spirito, Pescara, Italy, "
        ],
        [
            "Divisione di Ematologia, Presidio Ospedaliero\u201cA.Perrino\u201d,Brindisi, Italy, Brindisi, Italy, "
        ],
        [
            "UOS di Emato-Oncologia,, Ospedale Garibaldi-Nesima, Catania, Italy, Catania, Italy, "
        ],
        [
            "Ospedale Civile, Noale, Venezia, Italy, Venezia, Italy, "
        ],
        [
            "Divisione di Ematologia, Ospedale Policlinico, Palermo, Italy, Palermo, Italy, "
        ],
        [
            "Dipartimento di Ematologia, Venere,Bari, Italy, Bari, Italy, "
        ],
        [
            "Unita\u0300 Operativa di Medicina Interna, Presidio Ospedaliero di Matera, Italy, Matera, Italy, "
        ],
        [
            "CROB Rionero in Vulture, Roma, Italy, "
        ],
        [
            "Ematologia, A.O. Sant'Andrea, Universita' La Sapienza, Roma, Italy, Roma, Italy, "
        ],
        [
            "Centro di Riferimento Ematologico-Seconda Medicina, Azienda Ospedaliero-Universitaria, Ospedali Riuniti, Trieste, Italy, "
        ],
        [
            "Divisione di Ematologia, Azienda Ospedaliera, Reggio Calabria, Italy, "
        ],
        [
            "Division of Oncology, Modena University Hospital, Modena, Italy, "
        ],
        [
            "Dipartimento Scienze Mediche-Ematologia 1 CTMO, Universita\u0300 di Milano -Fondazione IRCCS Policlinico, Milan, Italy, "
        ],
        [
            "Department of Hematology, University of Milan, IRCCS Foundation Maggiore Policlinico Hospital, Milan, Italy, "
        ],
        [
            "Divisione di Ematologia, Universita\u0300 La Sapienza, Roma, Italy, "
        ],
        [
            "Dipartimento di Scienze Mediche, Centro di Ricerca per lo Studio delle Leucemie e U.O. Ematologia 1, Universita\u0300 di Milano e Fondazione IRCCS Policlinico, Milano, Italy, "
        ],
        [
            "Cattedra di Oncologia Medica, Universita\u0300 di Modena e Reggio Emilia, Modena, Italy, "
        ],
        [
            "Medical Oncology Center - Onclogy, Biology and Genetic Department, IST Genova - University of Genova, Genova, Italy, "
        ],
        [
            "Hematology, Azienda Ospedaliera Cosenza, Cosenza, Italy"
        ]
    ],
    "first_author_latitude": "38.9202449",
    "first_author_longitude": "16.5823473",
    "abstract_text": "Abstract 2375 Poster Board II-352 A prognostic index based on widely available clinical and laboratory features was recently proposed to predict survival in patients with previously untreated patients with chronic lymphocytic leukemia (CLL) by MD Anderson investigators. However, whether proposed clinical risk categories may surrogate new biological variables of prognostic relevance (i.e., mutational status of the IgVH gene regions, ZAP-70 or CD-38 expression, cytogenetic abnormalities) is unclear thus far. In a series of 160 asymptomatic Binet stage A patients enrolled in a Gruppo Italiano Studio Linfomi (GISL) multicentre trial designed to validate prospectively biological parameters in early CLL as well as to assess the impact on clinical outcome of an early versus delayed policy of treatment with subcutaneous alemtuzumab in the high biological risk, we evaluated whether clinical categories derived from newly proposed prognostic index reflected biological risk. Since the original prognostic index was derived from a database including cases with more advanced disease we used an optimal cutoff search to determine how to best split Binet stage A patients in different prognostic groups. To this purpose an independent patient cohort consisting of 310 Binet stage A patients included in a GIMEMA (Gruppo Italiano Malattie EMatologiche Maligne dell'Adulto) database was used. According to recursive partitioning (RPART) model, a classification tree was built that identified two subsets of patients who scored respectively: 0-3 (low risk) and 4-7 (high risk). Therefore, by prognostic index, 48.7% and 51.2% of 160 asymptomatic stage A patients, respectively, met criteria of low risk and high risk disease. In our prospective series high- risk score was more frequently associated with both unmutated IgVH status (P=0.009) and higher CD38-expression (P=0.002); in contrast only a trend towards an increased ZAP-70 expression could be found (P=0.06). As far as cytogenetic abnormalities are concerned, we observed that 11q deletion occurred more frequently among patients belonging to high-risk score (P=0.005), while cases with 13q deletion or trisomy 12 were homogeneously distributed among low- and high-risk patient category(P=0.151 and P=0.452, respectively). We did not consider suitable for correlation analysis 17p deletion since observed only in 2 out of 160 Binet stage A patients. In conclusion, our results demonstrate in a prospective cohort of patients with early CLL that clinical categories of a revised score index may surrogate biological parameters of prognostic relevance. The observation reinforces the revised IWCLL guidelines recommendations to assess the risk of CLL patients on clinical basis and to deserve biological studies to patients eligible for clinical trials. Disclosures: No relevant conflicts of interest to declare."
}